

Resource Summary Report

Generated by [NIF](#) on Aug 31, 2026

BT-549

RRID:CVCL_1092

Type: Cell Line

Proper Citation

RRID:CVCL_1092

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1092

Proper Citation: RRID:CVCL_1092

Description: Cell line BT-549 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Invasive breast carcinoma of no special type

Defining Citation: [PMID:1961733](#), [PMID:6500159](#), [PMID:7902062](#), [PMID:9331090](#), [PMID:9561029](#), [PMID:9671407](#), [PMID:10700174](#), [PMID:10862037](#), [PMID:10969801](#), [PMID:11343771](#), [PMID:15153330](#), [PMID:15677628](#), [PMID:15748285](#), [PMID:16397213](#), [PMID:16541312](#), [PMID:17088437](#), [PMID:17157791](#), [PMID:18277095](#), [PMID:18516279](#), [PMID:19372543](#), [PMID:19582160](#), [PMID:19593635](#), [PMID:19727395](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20679594](#), [PMID:21552935](#), [PMID:21778573](#), [PMID:22068913](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:22628656](#), [PMID:23151021](#), [PMID:23601657](#), [PMID:23637631](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24094812](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25892236](#), [PMID:25960936](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:28287265](#), [PMID:28889351](#), [PMID:30613774](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: BT-549

Synonyms: BT 549, BT.549, BT549

Cross References: BTO:BTO_0002548, CLO:CLO_0002044, EFO:EFO_0001096, CLDB:cl7128, AddexBio:C0006017/4962, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-6647, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:HTB-122, BioGRID_ORCS_Cell_line:510, BioSample:SAMN03471380, BioSample:SAMN10988343, cancercellines:CVCL_1092, CCRID:1101HUM-PUMC000336, CCRID:3101HUMTCHu93, Cell_Model_Passport:SIDM00122, ChEMBL-Cells:ChEMBL3308490, ChEMBL-Targets:ChEMBL614072, CLS:300132, Cosmic:687466, Cosmic:850826, Cosmic:871140, Cosmic:875881, Cosmic:877446, Cosmic:897414, Cosmic:904353, Cosmic:934522, Cosmic:949188, Cosmic:974237, Cosmic:1010925, Cosmic:1018476, Cosmic:1044204, Cosmic:1044234, Cosmic:1046924, Cosmic:1047700, Cosmic:1092593, Cosmic:1136371, Cosmic:1152525, Cosmic:1175830, Cosmic:1176638, Cosmic:1287920, Cosmic:1289385, Cosmic:1305386, Cosmic:1308998, Cosmic:1312372, Cosmic:1434948, Cosmic:1603193, Cosmic:1609466, Cosmic:1995350, Cosmic:1998435, Cosmic:2036671, Cosmic:2164983, Cosmic:2301524, Cosmic:2318374, Cosmic:2361359, Cosmic-CLP:905951, DepMap:ACH-000288, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905951, GEO:GSM2121, GEO:GSM50181, GEO:GSM50245, GEO:GSM217614, GEO:GSM274638, GEO:GSM274662, GEO:GSM320176, GEO:GSM344343, GEO:GSM344393, GEO:GSM350517, GEO:GSM378149, GEO:GSM421863, GEO:GSM750775, GEO:GSM783947, GEO:GSM799318, GEO:GSM799381, GEO:GSM827358, GEO:GSM839031, GEO:GSM843477, GEO:GSM843478, GEO:GSM843479, GEO:GSM843480, GEO:GSM846287, GEO:GSM847199, GEO:GSM847454, GEO:GSM886894, GEO:GSM887959, GEO:GSM1008893, GEO:GSM1053686, GEO:GSM1153387, GEO:GSM1172855, GEO:GSM1172943, GEO:GSM1181340, GEO:GSM1181341, GEO:GSM1214578, GEO:GSM1238130, GEO:GSM1374412, GEO:GSM1374413, GEO:GSM1401657, GEO:GSM1669632, GEO:GSM2124662, IARC_TP53:5, IARC_TP53:28243, IBRC:C10151, ICLC:HTL02006, KCB:KCB_2011118YJ, LiGeA:CCLE_360, LINCS_HMS:50108, LINCS_LDP:LCL-1310, Lonza:116, NCI-DTP:BT-549, PharmacDB:BT549_111_2019, PRIDE:PXD003539, PRIDE:PXD005292, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD008222, PRIDE:PXD030304, Progenetix:CVCL_1092, PubChem_Cell_line:CVCL_1092, SKY/M-FISH/CGH:1458, SLKBase:3393, TOKU-E:696, Wikidata:Q54798471

ID: CVCL_1092

Record Creation Time: 20220427T215414+0000

Record Last Update: 20260829T231647+0000

Ratings and Alerts

No rating or validation information has been found for BT-549.

No alerts have been found for BT-549.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 2466 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Pyun WY, et al. (2026) Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. *Cancer research*, 86(5), 1194.

Esapa B, et al. (2026) An antibody-drug conjugate designed through clone and isotype selection restricts the growth of CSPG4-expressing triple-negative breast cancer. *NPJ precision oncology*, 10(1).

Chen K, et al. (2026) Amino acid supplementation enhances in vivo efficacy of lipid nanoparticle-mediated mRNA delivery in preclinical models. *Science translational medicine*, 18(840), eadx4097.

Tong Q, et al. (2026) Detachment-Induced FAK-STAT3-NNMT Inhibits CTCs Anoikis to Promote Breast Cancer Metastasis by Enhancing Fatty Acid Oxidation. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(29), e22837.

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. *Cell reports. Medicine*, 7(4), 102694.

Boyer T, et al. (2026) Immunosuppressive myeloid cells induce mesenchymal-like breast cancer stem cells by a membrane-bound TGF- β 1-dependent mechanism. *Cell reports*, 45(7), 117568.

Alhourani F, et al. (2026) Targeting SUV4-20H Epigenetic Enzymes Enhances Topoisomerase II Poisoning in Prostate Cancer. *Cancer research*, 86(1), 236.

Lin W, et al. (2026) FAM135B Deficiency Inhibits Cytotoxic T-cell Activity in Triple-Negative Breast Cancer by Blocking the IFI16-Dependent STING Pathway. *Cancer immunology research*, 14(2), 335.

Singh D, et al. (2026) Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity. *Cancer research*, 86(5), 1252.

Xu Y, et al. (2026) Comprehensive single-cell metabolic profiling identifies targets to sensitize triple-negative breast cancer to chemo-immunotherapy. *Cell reports. Medicine*, 7(3), 102659.

Townsel A, et al. (2026) Early Epigenetic and Metabolic Responses to the Adipocyte Secretome Reveal Stress-Adaptive States in Triple-Negative Breast Cancer. *bioRxiv : the preprint server for biology*.

Chatterjee E, et al. (2026) Autophagy-lysosomal dependency defines a vulnerable physiological state in drug-tolerant persister cells of triple-negative breast cancer. *Apoptosis : an international journal on programmed cell death*, 31(5).

Rosado-Sanz M, et al. (2026) Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer. *Oncoimmunology*, 15(1), 2687381.

Liu Y, et al. (2026) Immune-associated alternative splicing signatures define molecular subtypes in breast cancer. *iScience*, 29(8), 116732.

Wang J, et al. (2026) Cyclic di-GMP suppresses cancer metastasis by targeting proteasome 26S subunit non-ATPase 3 independently of STING. *Signal transduction and targeted therapy*, 11(1), 44.

Tang S, et al. (2026) PTEN Loss Promotes PI3K γ Phosphorylation and EPHA2/SRC/p-PI3K γ Y962 Complex Assembly to Drive Tumorigenesis. *Cancer discovery*, 16(3), 521.

Ortega-Álvarez D, et al. (2026) Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies. *Cancer research*, 86(10), 2360.

Cobb DA, et al. (2026) γ -CD137 CAR-T Cells Simultaneously Targeting Tumor and Metastases Produce Highly Effective Control in Preclinical Models of Melanoma and Triple-Negative Breast Cancer. *Molecular cancer therapeutics*, 25(7), 1181.

Shi J, et al. (2026) TSPYL5 Promotes Triple-Negative Breast Cancer Metastasis by Antagonizing USP10-Mediated PTEN Stabilization to Unleash a ZEB1-Dependent EMT Program. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e20273.

Wang Q, et al. (2026) FANCA-dependent FEN1 recruitment suppresses transcription-replication conflicts and PARPi sensitivity. *Molecular cell*.